{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:01:32Z","timestamp":1785164492901,"version":"3.55.0"},"reference-count":26,"publisher":"Akademiai Kiado Zrt.","issue":"39","license":[{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,9,29]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    A myeloma multiplex t\u00fal\u00e9l\u00e9se sokat javult az ut\u00f3bbi\n                    k\u00e9t \u00e9vtizedben, ami els\u0151sorban az \u00faj kezel\u00e9si lehet\u0151s\u00e9gek megjelen\u00e9s\u00e9nek tudhat\u00f3\n                    be. \u00c1m a mindennapi \u00e9letben tapasztaltak sokszor elt\u00e9rhetnek a klinikai\n                    vizsg\u00e1latok eredm\u00e9nyeit\u0151l, ez\u00e9rt fontos a \u201ereal world\u201d adatok \u00f6sszegy\u0171jt\u00e9se is.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s \u00e9s m\u00f3dszer:<\/jats:italic>\n                    A Semmelweis Egyetem Belgy\u00f3gy\u00e1szati\n                    \u00e9s Hematol\u00f3giai Klinik\u00e1j\u00e1n (illetve el\u0151dj\u00e9ben, a III. Sz. Belgy\u00f3gy\u00e1szati\n                    Klinik\u00e1n) 2008 \u00e9s 2021 k\u00f6z\u00f6tt diagnosztiz\u00e1lt \u00f6sszes myelom\u00e1s beteg klinikai \u00e9s\n                    t\u00fal\u00e9l\u00e9si adatait elemezt\u00fck. Vizsg\u00e1ltuk az \u00f6sszef\u00fcgg\u00e9seket a diagn\u00f3zis id\u0151szaka,\n                    a kezel\u00e9si protokollok, a prognosztikai t\u00e9nyez\u0151k (International Staging System,\n                    karyotypus), a csontlaesi\u00f3k, a veseel\u00e9gtelens\u00e9g jelenl\u00e9te \u00e9s a t\u00fal\u00e9l\u00e9s k\u00f6z\u00f6tt.\n                    Klinik\u00e1nkon 2013-t\u00f3l myelomaspecifikus szakrendel\u00e9s keret\u00e9ben l\u00e1tjuk el a\n                    betegeket, ami szint\u00e9n kihathat a t\u00fal\u00e9l\u00e9sre.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    \u00d6sszesen 284 beteget diagnosztiz\u00e1ltunk a vizsg\u00e1lt id\u0151szakban, melynek sor\u00e1n az\n                    \u00e9vente felismert betegek sz\u00e1ma megh\u00e1romszoroz\u00f3dott. A kezel\u00e9si strat\u00e9gia\n                    nagym\u00e9rt\u00e9kben v\u00e1ltozott ek\u00f6zben: a kemoter\u00e1pi\u00e1t teljesen felv\u00e1ltotta az \u00faj\n                    szerek alkalmaz\u00e1sa, egyre ink\u00e1bb h\u00e1rmas vagy n\u00e9gyes kombin\u00e1ci\u00f3kban. A teljes\n                    csoport medi\u00e1nt\u00fal\u00e9l\u00e9se 54 h\u00f3nap volt, azonban szignifik\u00e1nsan k\u00fcl\u00f6nb\u00f6z\u00f6tt\n                    aszerint, hogy melyik korszakban t\u00f6rt\u00e9nt a diagn\u00f3zis. A 2008\u20132011 k\u00f6z\u00f6tt\n                    diagnosztiz\u00e1lt betegcsoport t\u00fal\u00e9l\u00e9se 35, 2012\u20132015 k\u00f6z\u00f6tt 44, 2016\u20132019 k\u00f6z\u00f6tt\n                    50 h\u00f3nap volt; a leg\u00fajabb, 2020 ut\u00e1ni id\u0151szak eset\u00e9n a t\u00fal\u00e9l\u00e9s m\u00e9g nem \u00e9rte el a\n                    medi\u00e1nt, de szignifik\u00e1nsan jobb a kor\u00e1bbi betegcsoportokkal \u00f6sszevetve.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    Vizsg\u00e1latunk al\u00e1t\u00e1masztotta, hogy az \u00faj\n                    gy\u00f3gyszerek bevezet\u00e9s\u00e9vel a v\u00e1rhat\u00f3 t\u00fal\u00e9l\u00e9s a val\u00f3 \u00e9letben kezelt betegek\n                    eset\u00e9ben is k\u00f6zel megdupl\u00e1z\u00f3dott. Ennek h\u00e1tter\u00e9ben els\u0151sorban az \u00e1llhat, hogy a\n                    kor\u00e1bbi id\u0151szakban jelent\u0151s korai hal\u00e1loz\u00e1s (refrakterit\u00e1s, szeptikus\n                    sz\u00f6v\u0151dm\u00e9nyek) a jobb ter\u00e1pi\u00e1k hat\u00e1s\u00e1ra lecs\u00f6kkent, illetve t\u00f6bb kezel\u00e9si vonal\n                    \u00e1ll rendelkez\u00e9s\u00fcnkre, de a myelomaspecifikus szakrendel\u00e9sen alkalmazott egys\u00e9ges\n                    szeml\u00e9let, a szoros monitoroz\u00e1s, a klinikai vizsg\u00e1latok el\u00e9rhet\u0151s\u00e9ge \u00e9s az \u00edgy\n                    \u00f6sszegy\u0171lt tapasztalat szint\u00e9n k\u00f6zrej\u00e1tszhat a pozit\u00edv eredm\u00e9nyekben. Orv Hetil.\n                    2024; 165(39): 1539\u20131547.\n                  <\/jats:p>","DOI":"10.1556\/650.2024.33120","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T06:21:24Z","timestamp":1727763684000},"page":"1539-1547","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["Myeloma multiplexben szenved\u0151 betegek t\u00fal\u00e9l\u00e9si eredm\u00e9nyei a Semmelweis Egyetem Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinik\u00e1j\u00e1n"],"prefix":"10.1556","volume":"165","author":[{"given":"Eszter","family":"Ruff","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Ga\u00e1l","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vir\u00e1g R\u00e9ka","family":"Szita","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1d\u00e1m","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Svorenj","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s D\u00e1vid","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Szombath","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Farkas","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"V\u00e1rkonyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Varga","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Varga G, Mikala G, V\u00e1r\u00f3czy L, et al. Management of multiple myeloma\n                    in Hungary in 2016. [A myeloma multiplex megk\u00f6zel\u00edt\u00e9se Magyarorsz\u00e1gon 2016-ban.]\n                    Orv Hetil. 2016; 157: 123\u2013137. [Hungarian]","DOI":"10.1556\/650.2016.30341"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, et al. Novel agents\n                    as main drivers for continued improvement in survival in multiple myeloma.\n                    Cancers 2023; 15: 1558.","DOI":"10.3390\/cancers15051558"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in\n                    survival in multiple myeloma: changes in early mortality and outcomes in older\n                    patients. Leukemia 2014; 28: 1122\u20131128.","DOI":"10.1038\/leu.2013.313"},{"key":"R4","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working\n                    Group consensus criteria for response and minimal residual disease assessment in\n                    multiple myeloma. Lancet Oncol. 2016; 17: e328\u2013e346."},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international\n                    staging system for multiple myeloma: a report from International Myeloma Working\n                    Group. J Clin Oncol. 2015; 33: 2863\u20132869.","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Turesson I, Bjorkholm M, Blimark CH, et al. Rapidly changing myeloma\n                    epidemiology in the general population: increased incidence, older patients, and\n                    longer survival. Eur J Haematol. 2018; 101: 237\u2013244.","DOI":"10.1111\/ejh.13083"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Swan D, Hayden PJ, Eikema DJ, et al. Trends in autologous stem cell\n                    transplantation for newly diagnosed multiple myeloma: changing demographics and\n                    outcomes in European Society for Blood and Marrow Transplantation centres from\n                    1995 to 2019. Br J Haematol. 2022; 197: 82\u201396.","DOI":"10.1111\/bjh.18025"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Lin CM, Chang LC, Shau WY, et al. Treatment benefit of upfront\n                    autologous stem cell transplantation for newly diagnosed multiple myeloma: a\n                    systematic review and meta-analysis. BMC Cancer 2023; 23: 446","DOI":"10.1186\/s12885-023-10907-1"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Remenyi P, Varga G, Mikala G, et al. Early versus delayed autologous\n                    stem cell transplantation and interferon maintenance in multiple myeloma:\n                    single-center experience of 18 years. Transplant Proc. 2016; 48:\n                    177\u2013184.","DOI":"10.1016\/j.transproceed.2015.12.031"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Mo CC, Hartley-Brown MA, Midha S, et al. Upfront or deferred\n                    autologous stem cell transplantation for newly diagnosed multiple myeloma in the\n                    era of triplet and quadruplet induction and minimal residual\n                    disease\/risk-adapted therapy. Cancers (Basel) 2023; 15: 5709.","DOI":"10.3390\/cancers15245709"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Tanguay M, Dagenais C, LeBlanc R, et al. Young myeloma patients: a\n                    systematic review of manifestations and outcomes. Curr Oncol. 2023; 30:\n                    5214\u20135226.","DOI":"10.3390\/curroncol30060396"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Szita VR, Wiedemann \u00c1, Syoreni Sz, et al. Venetoclax-based salvage\n                    in multiple myeloma with (11;14) translocation after suboptimal response to\n                    first-line therapy. [Venetoclaxalap\u00fa ment\u0151kezel\u00e9s (11;14)-transzlok\u00e1ci\u00f3s myeloma\n                    multiplexben az els\u0151 vonalbeli kezel\u00e9sre adott nem megfelel\u0151 v\u00e1lasz eset\u00e9n.] Orv\n                    Hetil. 2023; 164: 894\u2013899. [Hungarian]","DOI":"10.1556\/650.2023.32790"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Freeman AT, Kuo M, Zhou L, et al. Influence of treating facility,\n                    provider volume, and patient-sharing on survival of patients with multiple\n                    myeloma. J Natl Compr Canc Netw. 2019; 17: 1100\u20131108.","DOI":"10.6004\/jnccn.2019.7298"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Mai EK, Hielscher T, Bertsch U, et al. Predictors of early morbidity\n                    and mortality in newly diagnosed multiple myeloma: data from five randomized,\n                    controlled, phase III trials in 3700 patients. Leukemia 2024; 38:\n                    640\u2013647.","DOI":"10.1038\/s41375-023-02105-6"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Kor\u00f3zs D, Jen\u0151fi N, Szab\u00f3 BG, et al. \u201cWhen it rains, it pours\u201d \u2013\n                        de novo diagnosed multiple myeloma with invasive\n                        Streptococcus pneumoniae infection in severe COVID\u201319\n                    complicated with cytokine storm. [\u201eA baj nem j\u00e1r egyed\u00fcl\u201d \u2013 de\n                        novo diagnosztiz\u00e1lt myeloma multiplex invaz\u00edv Streptococcus\n                        pneumoniae fert\u0151z\u00e9ssel citokinviharral sz\u00f6v\u0151d\u00f6tt COVID\u201319-ben.] Orv\n                    Hetil. 2023; 164: 763\u2013769. [Hungarian]","DOI":"10.1556\/650.2023.32785"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Frank N, Csik\u00f3s \u00c1. Practical application of steroids in palliative\n                    therapy. [Szteroidok gyakorlati alkalmaz\u00e1sa a palliat\u00edv ter\u00e1pi\u00e1ban.] Orv Hetil.\n                    2022; 163: 294\u2013300. [Hungarian]","DOI":"10.1556\/650.2022.32374"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"T\u00f3th T, Alizadeh H. On the threshold of a possible cure: innovations\n                    in treating multiple myeloma. [Az el\u00e9rhet\u0151 gy\u00f3gyul\u00e1s k\u00fcsz\u00f6b\u00e9n: innov\u00e1ci\u00f3k a\n                    myeloma multiplex kezel\u00e9s\u00e9ben.] Orv Hetil. 2024; 165: 891\u2013899.\n                    [Hungarian]","DOI":"10.1556\/650.2024.33036"},{"key":"R18","unstructured":"Waszczuk-Gajda A, Szafraniec-Bury\u0142o S, Kraj L, et al. Epidemiology\n                    of multiple myeloma in Poland in the years 2008\u20132017. Arch Med Sci. 2023; 19:\n                    645\u2013650."},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Popkova T, Pour L, Spicka I, et al. Survival analysis of newly\n                    diagnosed transplant-eligible multiple myeloma patients in Czech Republic. Blood\n                    2021; 138(Suppl 1): 4894.","DOI":"10.1182\/blood-2021-153978"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"H\u00e1jek R, Jarkovsky J, Maisnar V, et al. Real-world outcomes of\n                    multiple myeloma: retrospective analysis of the Czech Registry of Monoclonal\n                    Gammopathies. Clin Lymphoma Myeloma Leuk. 2018; 18: e219\u2013e240.","DOI":"10.1016\/j.clml.2018.04.003"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"\u0218tefan G, Cinca S, Chiriac C, et al. Multiple myeloma and kidney\n                    impairment at diagnosis: a nephrological perspective from an Eastern European\n                    country. Medicina (Kaunas) 2023; 59: 1326.","DOI":"10.3390\/medicina59071326"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Irimia R, Badelita S, Barbu S, et al. Determining diagnostic delays\n                    in Romanian multiple myeloma patients using the Aarhus statement. Front Med.\n                    2024; 11: 1372907.","DOI":"10.3389\/fmed.2024.1372907"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Varga G, Mikala G, Andrikovics H, et al. How long does a myeloma\n                    patient currently wait for the diagnosis in Hungary? [Menynyit v\u00e1r ma\n                    Magyarorsz\u00e1gon egy myelom\u00e1s beteg a diagn\u00f3zisig?] Orv Hetil. 2014; 155:\n                    1538\u20131543. [Hungarian]","DOI":"10.1556\/OH.2014.30000"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"\u0106ojba\u0161i\u0107 I, Vu\u010di\u0107 M, Tijani\u0107 I, et al. Impact of quality of response\n                    on survival outcomes among multiple myeloma patients treated with novel agents \u2013\n                    a retrospective analysis. Sao Paulo Med J. 2022; 140: 222\u2013228.","DOI":"10.1590\/1516-3180.2021.0174.r2.22062021"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Eisfeld C, Kaj\u00fcter H, M\u00f6ller L, et al. Time trends in survival and\n                    causes of death in multiple myeloma: a population-based study from Germany. BMC\n                    Cancer 2023; 23: 317.","DOI":"10.1186\/s12885-023-10787-5"},{"key":"R26","unstructured":"Myeloma Patients Europe. Myeloma Access Atlas. Data and statistics\n                    for incidence and mortality of multiple myeloma. Available from:\n                        https:\/\/atlas.mpeurope.org\/data-and-statistics [accessed: June\n                    14, 2024]."}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/39\/article-p1539.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/39\/article-p1539.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/39\/article-p1539.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:18:49Z","timestamp":1785161929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/39\/article-p1539.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,29]]},"references-count":26,"journal-issue":{"issue":"39"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.33120","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,29]]}}}